About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:5823559
Allelic
Composition
Sf3b1tm1.1Mdf/Sf3b1+
Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(Mx1-cre)1Cgn/?
Genetic
Background
involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Sf3b1tm1.1Mdf mutation (1 available); any Sf3b1 mutation (51 available)
Tet2tm1.1Iaai mutation (1 available); any Tet2 mutation (736 available)
Tg(Mx1-cre)1Cgn mutation (6 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• block in erythroblast development results in an increase in cells at development stage R2 and a decrease in R4 population in spleen by 12 weeks post-piPC
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with pIPC results in increasing (46.5% to 90%) donor chimerism beginning at 16 weeks post transplantation as compared to mice carrying only the Sf3b1tm1.1Mdf allele and wild-type
• progressive macrocytic anemia 45 weeks post pIPC treatment
• spleens contain dysplastic megakaryocytes 45 weeks post-piPC treatment
• spleens contain dysplastic erythroid progenitors 45 weeks post-piPC treatment
• observed at 45 weeks post-pIPC injection
• phenotype is increased in severity as compared to mice carrying only the Sf3b1tm1.1Mdf allele
• post-pIPC treatment
• increased percentage of granulocytes in peripheral blood and bone marrow at 45 weeks post-pIPC
• decrease in percentage of B cells in the spleen and bone marrow 45 weeks post-pIPC
• increase in long term repopulating hematopoietic stem cells (LT-HSC) at 12 and 45 weeks as compared to wild-type
• increase in multi-potent progenitors (MPP) in bone marrow 12 weeks post-piPC treatment
• post-piPC treatment

immune system
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with pIPC results in increasing (46.5% to 90%) donor chimerism beginning at 16 weeks post transplantation as compared to mice carrying only the Sf3b1tm1.1Mdf allele and wild-type
• increased percentage of granulocytes in peripheral blood and bone marrow at 45 weeks post-pIPC
• decrease in percentage of B cells in the spleen and bone marrow 45 weeks post-pIPC
• post-piPC treatment

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
myelodysplastic syndrome DOID:0050908 OMIM:614286
J:234976


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
11/14/2017
MGI 6.11
The Jackson Laboratory